Core Viewpoint - The stock market experienced fluctuations, particularly in the pharmaceutical sector, but the company's fundamentals and long-term industry trends remain positive [1][2] Group 1: Stock Performance - On June 17, the Hong Kong stock market indices showed a downward trend, with the Hang Seng Index falling by 0.34%, the Hang Seng China Enterprises Index down by 0.4%, and the Hang Seng Tech Index decreasing by 0.15% [1] - Pharmaceutical stocks generally retreated, with the company, Yaoshi Bang (9885.HK), dropping by 6.31% to close at 10.4 HKD [1] Group 2: Company Actions - In response to stock price volatility, the company has been actively repurchasing shares and increasing executive holdings to stabilize market expectations [1] - On June 17, the company repurchased 100,000 shares at a total cost of approximately 1.03 million HKD, averaging 10.31 HKD per share [1] - Since initiating a billion HKD repurchase plan on May 7, the company has repurchased a total of 5.53 million shares, with a total repurchase amount exceeding 43.34 million HKD [1] - Executive Director Chen Fei also increased his holdings by 100,000 shares on June 17, bringing the total to over 900,000 shares, reflecting management's confidence in the company's future [1] Group 3: Financial Performance - The company has released positive signals this year, achieving its first annual profit in 2024, with a net profit of 157 million HKD, representing a year-on-year increase of 20.1% [1] - High-margin business growth has accelerated, with the transaction scale of the brand's first-push business reaching 717 million HKD from January to April, a year-on-year increase of 108.1% [1] - The company's proprietary brand business reached 560 million HKD, showing a significant year-on-year growth of 532.3%, indicating the formation of new growth momentum [1] Group 4: Industry Trends - The company is adapting to future pharmacy industry upgrades by entering the fields of pharmaceutical robotics and AI models [2] - In June, the company formed a strategic partnership with leading collaborative robotics firm, Yuejiang Technology, to explore high-value-added business opportunities in new retail scenarios through pharmaceutical collaborative robots, AI models, and drug IoT technologies [2] - Industry experts believe that the recent decline in the pharmaceutical sector is more related to technical adjustments following profit-taking rather than direct impacts from industrial policies or significant fundamental changes [2]